BlossomHill Therapeutics, Inc.(BLSM)

Biotechnology · San Diego, CA

$17.29-2.65 (-13.29%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

EBITDA Yield: N/A

Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.

The EBITDA yield is N/A as of 2026-10-06T21:50:59.196Z.

Stored calculation inputs

Calculation as of: 2026-10-06T21:50:59.196Z.

Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.

TTM operating EBITDA · period ending 2026-06-30: N/A
Quote market capitalization: 502,813,256
Total debt · period ending 2026-06-30: 23,371,000
Cash · period ending 2026-06-30: 95,376,000

FMP input reference: ade6551c806a0b8a23cc3b9f653dfce73cf5104c20f92b5c51aa4b81f5201f45

EV/EBITDA|Earnings Yield|OCF Yield|FCF Yield|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

BLSM EBITDA Yield Metrics

EBITDA YIELD

N/A

BLSM Competitors' EBITDA Yield

BLSM

BlossomHill Therapeutics, Inc.

Current

Market Cap

$502.81M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ALLO

Allogene Therapeutics, Inc.

vs BLSM

Market Cap

$503.93M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CBIO

Crescent Biopharma, Inc.

vs BLSM

Market Cap

$504.04M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

TCMD

Tactile Systems Technology, Inc.

vs BLSM

Market Cap

$500.52M

EBITDA Yield

9.38%

TTM Avg

6.87%

3Y Avg

8.16%

5Y Avg

6.43%

MASS

908 Devices Inc.

vs BLSM

Market Cap

$505.87M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

OCS

Oculis Holding AG

vs BLSM

Market Cap

$498.52M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ACRS

Aclaris Therapeutics, Inc.

vs BLSM

Market Cap

$516.76M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ALT

Altimmune, Inc.

vs BLSM

Market Cap

$519.25M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

EOLS

Evolus, Inc.

vs BLSM

Market Cap

$486.01M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PBYI

Puma Biotechnology, Inc.

vs BLSM

Market Cap

$483.54M

EBITDA Yield

9.61%

TTM Avg

13.75%

3Y Avg

18.95%

5Y Avg

18.84%

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
BlossomHill Therapeutics, Inc. (BLSM)	$502.81M	N/A	N/A	N/A	N/A
Allogene Therapeutics, Inc. (ALLO)vs ›	$503.93M	N/A	N/A	N/A	N/A
Crescent Biopharma, Inc. (CBIO)vs ›	$504.04M	N/A	N/A	N/A	N/A
Tactile Systems Technology, Inc. (TCMD)vs ›	$500.52M	9.38%	6.87%	8.16%	6.43%
908 Devices Inc. (MASS)vs ›	$505.87M	N/A	N/A	N/A	N/A
Oculis Holding AG (OCS)vs ›	$498.52M	N/A	N/A	N/A	N/A
Aclaris Therapeutics, Inc. (ACRS)vs ›	$516.76M	N/A	N/A	N/A	N/A
Altimmune, Inc. (ALT)vs ›	$519.25M	N/A	N/A	N/A	N/A
Evolus, Inc. (EOLS)vs ›	$486.01M	N/A	N/A	N/A	N/A
Puma Biotechnology, Inc. (PBYI)vs ›	$483.54M	9.61%	13.75%	18.95%	18.84%

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EBITDA Yield: N/A

BLSM EBITDA Yield Metrics

BLSM Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics